• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recent advances in the chemotherapy of metastatic osteogenic sarcoma.

作者信息

Jaffe N

出版信息

Cancer. 1972 Dec;30(6):1627-31. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h.

DOI:10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h
PMID:4539306
Abstract
摘要

相似文献

1
Recent advances in the chemotherapy of metastatic osteogenic sarcoma.转移性骨肉瘤化疗的最新进展
Cancer. 1972 Dec;30(6):1627-31. doi: 10.1002/1097-0142(197212)30:6<1627::aid-cncr2820300631>3.0.co;2-h.
2
High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.大剂量甲氨蝶呤联合亚叶酸钙解救及阿霉素治疗儿童骨肉瘤
Cancer. 1974 Apr;33(4):1151-63. doi: 10.1002/1097-0142(197404)33:4<1151::aid-cncr2820330439>3.0.co;2-8.
3
Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.转移性骨肉瘤对大剂量甲氨蝶呤冲击治疗联合亚叶酸钙解救及放射治疗的良好反应。
Cancer. 1973 Jun;31(6):1367-73. doi: 10.1002/1097-0142(197306)31:6<1367::aid-cncr2820310611>3.0.co;2-6.
4
Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.大剂量甲氨蝶呤（NSC-740）联合亚叶酸钙解救治疗转移性骨肿瘤的进展报告
Cancer Chemother Rep. 1974 Mar-Apr;58(2):275-80.
5
The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma.多药化疗治疗骨肉瘤的理论依据。
Cancer. 1975 Mar;35(3 suppl):936-45. doi: 10.1002/1097-0142(197503)35:3+<936::aid-cncr2820350714>3.0.co;2-b.
6
Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.间歇性大剂量甲氨蝶呤-“亚叶酸钙解救”治疗儿童恶性肿瘤的临床试验及药代动力学
Cancer Res. 1974 Dec;34(12):3326-31.
7
High-dose methotrexate in osteogenic sarcoma: a 5-year experience.高剂量甲氨蝶呤治疗骨肉瘤：5年经验
Cancer Treat Rep. 1978 Feb;62(2):259-64.
8
The potential for an improved prognosis with chemotherapy in osteogenic sarcoma.骨肉瘤化疗改善预后的潜力。
Clin Orthop Relat Res. 1975 Nov-Dec(113):111-8. doi: 10.1097/00003086-197511000-00016.
9
Letter: Methotrexate-citrovorum factor in treating osteogenic sarcoma.信函：甲氨蝶呤-亚叶酸在治疗骨肉瘤中的应用
N Engl J Med. 1975 May 22;292(21):1133-4. doi: 10.1056/NEJM197505222922123.
10
High-dose methotrexate for the patient with osteogenic sarcoma.大剂量甲氨蝶呤用于骨肉瘤患者。
Am J Nurs. 1976 Nov;76(11):1776-80.

引用本文的文献

1
Prediction of High-Dose Methotrexate Blood Concentration in Osteosarcoma Patients Using Machine Learning.利用机器学习预测骨肉瘤患者大剂量甲氨蝶呤血药浓度
Drug Des Devel Ther. 2025 May 3;19:3631-3643. doi: 10.2147/DDDT.S515535. eCollection 2025.
2
Novel lipid metabolism factor HIBCH inhibitor synergizes with doxorubicin to suppress osteosarcoma growth and impacts clinical prognosis in osteosarcoma patients.新型脂质代谢因子HIBCH抑制剂与阿霉素协同作用，抑制骨肉瘤生长并影响骨肉瘤患者的临床预后。
J Bone Oncol. 2024 Nov 24;49:100652. doi: 10.1016/j.jbo.2024.100652. eCollection 2024 Dec.
3
Bone scaffolds-based localized drugs delivery for osteosarcoma: current status and future perspective.
基于骨支架的骨肉瘤局部药物递送：现状与展望。
Drug Deliv. 2024 Dec;31(1):2391001. doi: 10.1080/10717544.2024.2391001. Epub 2024 Sep 6.
4
Engineering small-molecule and protein drugs for targeting bone tumors.设计用于靶向骨肿瘤的小分子和蛋白质药物。
Mol Ther. 2024 May 1;32(5):1219-1237. doi: 10.1016/j.ymthe.2024.03.001. Epub 2024 Mar 6.
5
The Survival Outcomes, Prognostic Factors and Adverse Events following Systemic Chemotherapy Treatment in Bone Sarcomas: A Retrospective Observational Study from the Experience of the Cancer Referral Center in Northern Thailand.骨肉瘤全身化疗后的生存结果、预后因素及不良事件：一项基于泰国北部癌症转诊中心经验的回顾性观察研究。
Cancers (Basel). 2023 Mar 26;15(7):1979. doi: 10.3390/cancers15071979.
6
Bone sarcoma: success through interdisciplinary collaboration.骨肉瘤：通过跨学科协作取得成功。
J Child Orthop. 2021 Aug 20;15(4):331-336. doi: 10.1302/1863-2548.15.210122.
7
Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.骨肉瘤的辅助和新辅助化疗：历史观点。
Adv Exp Med Biol. 2020;1257:1-10. doi: 10.1007/978-3-030-43032-0_1.
8
Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial.二期、多中心、开放标签、单臂临床试验，评估霉酚酸酯在高级别局部晚期或转移性骨肉瘤（ESMMO）患者中的疗效和安全性：ESMMO 试验的原理和设计。
BMC Cancer. 2020 Mar 30;20(1):268. doi: 10.1186/s12885-020-06751-2.
9
Identification and Validation of a Potent Multi-miRNA Signature for Prediction of Prognosis of Osteosarcoma Patients.鉴定和验证一个有效的多 miRNA 标志物，用于预测骨肉瘤患者的预后。
Med Sci Monit. 2020 Feb 26;26:e919272. doi: 10.12659/MSM.919272.
10
Progress in the chemotherapeutic treatment of osteosarcoma.骨肉瘤化疗治疗的进展
Oncol Lett. 2018 Nov;16(5):6228-6237. doi: 10.3892/ol.2018.9434. Epub 2018 Sep 12.